SNY

MKT CAP:$113B

Sanofi

Market Cap

$113B

Healthcare·Drug Manufacturers - General·🇫🇷 France·NASDAQ

Healthcare·Drug Mfg.·🇫🇷·NASDAQ

Stock Price

$46.94-$1.29 (-2.67%)

Apr 24, 2026

Company Details

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccin...

CEO

Olivier Charmeil

IPO Date

Jul 1, 2002

Website

www.sanofi.com

Key Metrics TTM

Revenue

$58.8B

+12.5% YoY

Net Income

$10.2B

EPS (Diluted)

$2.82

Free Cash Flow

$7.2B

Revenue / Share

$24.08

Gross Margin

71.9%

Operating Margin

15.3%

Net Margin

17.4%

FCF Margin

12.3%

P/S

1.9x

P/E

11.1x

Earnings Reports

FY 2025

Feb 17, 2026

$54.6BEPS $2.37

Q4 2025

Jan 29, 2026

$14.3BEPS -$1.71

Q3 2025

Oct 24, 2025

$15.4B-7.0%EPS $1.33

Q2 2025

Jul 31, 2025

$12.6B-5.7%EPS $1.87

Q3 2024

Sep 30, 2024

$16.6B+11.5%EPS $1.32

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 19	$10.5B	$7.3B	-$347M
Q3 19	$11.6B	$7.9B	$2.5B
Q1 20	$10.9B	$7.5B	$2.4B
Q3 20	$11.6B	$7.8B	$3.0B
Q1 21	$10.4B	$7.3B	$2.4B
Q3 21	$12.7B	$8.9B	$3.5B
Q1 22	$11.8B	$8.4B	$2.8B
Q3 22	$15.4B	$10.9B	$3.2B
Q1 23	$12.7B	$9.1B	$2.9B
Q3 23	$14.8B	$10.4B	$3.8B
Q1 24	$11.4B	$7.9B	$1.4B
Q2 24	$13.3B	$9.3B	$1.9B
Q3 24	$16.6B	$11.8B	$4.2B
Q2 25	$12.6B	$9.1B	$1.7B
Q3 25	$15.4B	$11.4B	$4.2B
Q4 25	$14.3B	$10.0B	-$1.2B

Valuation

Quarter	P/S	P/E
Q2 19	1.3x	13.0x
Q3 19	1.3x	16.2x
Q1 20	1.3x	10.6x
Q3 20	1.4x	10.3x
Q1 21	1.4x	7.6x
Q3 21	1.3x	6.9x
Q1 22	1.4x	7.1x
Q3 22	1.0x	5.3x
Q1 23	1.3x	6.9x
Q3 23	1.2x	6.7x
Q1 24	1.1x	6.7x
Q2 24	1.2x	7.9x
Q3 24	1.3x	8.1x
Q2 25	1.1x	5.7x
Q3 25	1.9x	9.0x
Q4 25	2.0x	11.5x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 19	$0	$0
Q3 19	$0	$0
Q1 20	$0	$0
Q3 20	$0	$0
Q1 21	$0	$0
Q3 21	$0	$0
Q1 22	$0	$0
Q3 22	$0	$0
Q1 23	$0	$0
Q3 23	$0	$0
Q1 24	$0	$0
Q2 24	$1.7B	-$589M
Q3 24	$0	$0
Q2 25	$0	$0
Q3 25	$4.4B	$5.4B
Q4 25	$4.0B	$1.9B

Capital Expenditures

Quarter	CapEx
Q2 19	$0
Q3 19	$0
Q1 20	$0
Q3 20	$0
Q1 21	$0
Q3 21	$0
Q1 22	$0
Q3 22	$0
Q1 23	$0
Q3 23	$0
Q1 24	$0
Q2 24	$2.2B
Q3 24	$0
Q2 25	$0
Q3 25	$988M
Q4 25	$2.2B

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 19	+5.9%	+23.4%
Q3 19	+1.8%	+10.8%
Q1 20	-0.1%	-23.7%
Q3 20	+13.4%	+0.7%
Q1 21	-1.0%	-26.4%
Q3 21	+9.2%	+0.1%
Q1 22	+7.9%	+5.3%
Q3 22	+33.0%	+41.6%
Q1 23	+22.2%	+23.0%
Q3 23	+17.3%	+21.7%
Q1 24	-3.3%	+10.9%
Q2 24	-13.4%	-6.0%
Q3 24	+30.3%	+25.3%
Q2 25	-15.5%	-2.4%
Q3 25	+35.4%	+12.4%
Q4 25	+7.2%	+35.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 19	$153M	1.5%
Q3 19	$0	0.0%
Q1 20	$0	0.0%
Q3 20	$0	0.0%
Q1 21	$0	0.0%
Q3 21	$0	0.0%
Q1 22	$0	0.0%
Q3 22	$0	0.0%
Q1 23	$0	0.0%
Q3 23	$0	0.0%
Q1 24	$0	0.0%
Q2 24	$202M	1.5%
Q3 24	$0	0.0%
Q2 25	$200M	1.6%
Q3 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q2 19	$1.9B	$2.9B
Q3 19	$1.6B	$2.7B
Q1 20	$1.6B	$2.7B
Q3 20	$1.5B	$2.6B
Q1 21	$1.5B	$2.6B
Q3 21	$1.7B	$2.6B
Q1 22	$1.7B	$2.8B
Q3 22	$2.0B	$3.1B
Q1 23	$1.8B	$3.0B
Q3 23	$1.9B	$3.0B
Q1 24	$2.0B	$2.5B
Q2 24	$2.0B	$3.1B
Q3 24	$2.2B	$3.1B
Q2 25	$2.2B	$3.1B
Q3 25	$2.1B	$2.7B
Q4 25	$2.7B	$2.8B

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$11.8B	$0	$11.8B
Q1 22	$0	$23.6B	$23.6B
Q2 22	$8.1B	$0	$8.1B
Q3 22	$0	$16.1B	$16.1B
Q4 22	$14.9B	$0	$14.9B
Q1 23	$0	$29.8B	$29.8B
Q2 23	$9.3B	$0	$9.3B
Q3 23	$0	$18.7B	$18.7B
Q4 23	$10.2B	$0	$10.2B
Q1 24	$0	$20.4B	$20.4B
Q2 24	$7.9B	$0	$7.9B
Q4 24	$8.7B	$568M	$9.3B
Q1 25	$9.3B	$0	$9.3B
Q2 25	$18.0B	$0	$18.0B
Q3 25	$10.4B	$0	$10.4B
Q4 25	$9.0B	$0	$9.0B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 19	2.50B	+0.3%	+0.1%
Q3 19	2.50B	+0.3%	+0.4%
Q1 20	2.50B	-0.1%	+0.5%
Q3 20	2.51B	+0.4%	+0.8%
Q1 21	2.50B	-0.5%	+0.0%
Q3 21	2.51B	+0.4%	+0.2%
Q1 22	2.50B	-0.4%	-0.2%
Q3 22	2.51B	+0.3%	-0.2%
Q1 23	2.50B	-0.3%	+0.0%
Q3 23	2.51B	+0.3%	-0.1%
Q1 24	2.50B	-0.4%	-0.0%
Q2 24	2.50B	+0.2%	-0.2%
Q3 24	2.51B	+0.2%	+0.3%
Q2 25	2.47B	-1.5%	-1.5%
Q3 25	2.47B	0.0%	-1.2%
Q4 25	2.44B	-1.1%	-2.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 19	$100.7K	104K
Q3 19	$111.3K	104K
Q1 20	$108.5K	100K
Q3 20	$115.0K	100K
Q1 21	$104.5K	99K
Q3 21	$127.4K	99K
Q1 22	$123.2K	95K
Q3 22	$160.9K	95K
Q1 23	$138.7K	92K
Q3 23	$162.1K	92K
Q1 24	$132.1K	86K
Q2 24	$154.6K	86K
Q3 24	$192.3K	86K
Q2 25	$151.4K	83K
Q3 25	$185.8K	83K
Q4 25	$47.6K	300K

Revenue / Employee